Common use of Royalty Reductions Clause in Contracts

Royalty Reductions. (a) In the event that, during the Royalty Term for a Licensed Product and a country, (i) at the time of the First Commercial Sale of such Licensed Product in such country there is no Valid Claim that is infringed by the sale of such Licensed Product in such country for so long as there is no such Valid Claim, or (ii) if any such Valid Claim did exist as of such First Commercial Sale or thereafter but such Valid Claim has expired or otherwise no longer meets the definition of Valid Claim, then for any royalty payments made during the period when the condition set forth in (i) or (ii) exists with respect to such Licensed Product and such country, the royalties payable with respect to Net Sales of such Licensed Product sold by Jazz, its Affiliates and its Sublicensees in such country shall be reduced by [***] of the royalties otherwise owed to Codiak pursuant to this Section 8.10. In addition, if in any country in the Territory during the Royalty Term for a Licensed Product for such country, a Biosimilar/Generic Product is sold in such country and, according to a reasonable information source or reasonable proxy mutually agreed by the Parties, the units sold of all Biosimilar/Generic Products, collectively, exceed [***] or more of the unit sales of such Licensed Product in such country, then thereafter, the royalties payable with respect to Net Sales of such Licensed Product sold by Jazz, its Affiliates and its Sublicensees in such country shall be reduced by [***] of the royalties otherwise owed to Codiak pursuant to this Section 8.10. The reductions provided for by this Section 8.10.2(a) shall be calculated using the methodology outlined in Exhibit D.

Royalty Reductions. (a) In the event that, during the Royalty Term for a Licensed Product If and a country, (i) at the time of the First Commercial Sale of such Licensed Product in such country there is no Valid Claim that is infringed by the sale of such Licensed Product in such country for so long as there is no such Valid Claim, a Biosimilar Product or (ii) if any such Valid Claim did exist as of such First Commercial Sale or thereafter but such Valid Claim has expired or otherwise no longer meets Generic Product being sold by a Third Party in a Calendar Quarter in a country in the definition of Valid ClaimTerritory, then for any royalty payments made during the period when the condition set forth in (i) or (ii) exists with respect to such Licensed Product and such country, the royalties otherwise payable with respect by Takeda to Net Sales of such Licensed Product sold by Jazz, its Affiliates and its Sublicensees MTEM in such country pursuant to Section 6.8 above shall be reduced by [***] the percent set forth below of the royalties amounts otherwise owed to Codiak pursuant to this Section 8.10. In addition, if in any country in the Territory during the Royalty Term owed: Biosimilar Products or Generic Products unit volume sales for a Licensed Product for such country, a Biosimilar/Generic Product is sold in such country and, according to a reasonable information source or reasonable proxy mutually agreed by the Parties, the units sold of all Biosimilar/Generic Products, collectively, exceed [***] or more of the unit sales of such each Licensed Product in such country, then thereafteras a percentage of total sales of Licensed Products, on the royalties payable with respect to Net Sales of such Licensed Product sold by Jazzone hand, its Affiliates and its Sublicensees Biosimilar Products and Generic Products, on the other hand, in such country shall be reduced by Reduction rate [***] [***] Greater than [***] up to [***] [***] Greater than [***] up to [***] [***] Greater than [***] up to [***] [***] Greater than [***] [***] The Parties will select a mutually agreeable independent Third Party to identify and calculate the Biosimilar Products or Generic Products unit volume sales for each Licensed Product in a Calendar Quarter in a country in the Territory and such unit volume sales amounts shall be included in each royalty report provided for under Section 6.144. In the event that such independent Third Party is not available or Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the royalties Securities Exchange Act of 1934, as amended. otherwise owed able to Codiak accurately determine or calculate the Biosimilar Product or Generic Product unit volume sales, Takeda shall calculate the Biosimilar Product or Generic Product unit volume sales based on available data in good faith. In the event MTEM disputes Takeda’s calculation of any Biosimilar Product or Generic Product unit volume sales for a Licensed Product in a country in the Territory, MTEM may by written notice to Takeda require, at MTEM’s cost, that such dispute be resolved in accordance with Section 12.3 by and submitted to a panel of experts; provided, that Takeda shall have the right to take royalty reductions pursuant to this Section 8.10. The reductions provided for by this Section 8.10.2(a) shall be 6.8.2 pending resolution of any such dispute, calculated using its good faith calculation of the methodology outlined in Exhibit D.Biosimilar Product or Generic Product unit volume sales pursuant to the preceding sentence.

Royalty Reductions. (a) In the event that, during the Royalty Term for a Licensed Product and a country, (i) at the time of the First Commercial Sale of such Licensed Product in such country there is no Valid Claim that is infringed by the sale of such Licensed Product in such country for so long as there is no such Valid Claim, or (ii) if any such Valid Claim did exist as of such First Commercial Sale or thereafter but such Valid Claim has expired or otherwise no longer meets the definition of Valid Claim, then for any royalty payments made during the period when the condition set forth in (i) or (ii) exists with respect to such Licensed Product and such country, the royalties payable with respect to Net Sales of such Licensed Product sold by Jazz, its Affiliates and its Sublicensees in such country shall be reduced by [***] of the royalties otherwise owed to Codiak pursuant to this Section 8.10. In addition, if in any country in the Territory during the Royalty Term for a Licensed Product for such country, a Biosimilar/Generic Product is sold in such country and, according to a reasonable information source or reasonable proxy mutually agreed by the Parties, the units sold of all Biosimilar/Generic Products, collectively, exceed [***] or more of the unit sales of such Licensed Product in such country, then thereafter, the royalties payable with respect to Net Sales of such Licensed Product sold by Jazz, its Affiliates and its Sublicensees in such country shall be reduced by [***] of the royalties otherwise owed to Codiak pursuant to this Section 8.10. The reductions provided for by this Section 8.10.2(a) shall be calculated using the methodology outlined in Exhibit D.D. [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED

Royalty Reductions. (a) In the event thatAmicus shall be responsible for paying any royalties owed to Third Parties under Amicus’ Existing In-Licenses. However, during the Royalty Term for royalty term (as determined under Section 7.3.6) where a reduction of royalties due to Amicus under Section 7.3 with respect to a Licensed Product and in a country, (i) at the time country of the First Commercial Sale Shire Territory occurs under Sections 7.3.2, 7.3.3, 7.3.4, 7.3.6 or 15.5.4 of this Agreement [***] with respect to sales of such Licensed Product in such country there is no Valid Claim that is infringed by the sale of such Licensed Product in such country for so long as there is no such Valid Claimcountry, or (ii) if any such Valid Claim did exist as of such First Commercial Sale or thereafter but such Valid Claim has expired or otherwise no longer meets the definition of Valid ClaimShire shall promptly reimburse Amicus [***]. If, then for any royalty payments made during the period when the condition set forth in (i) or (ii) exists with respect to such a Licensed Product and such countryProduct, upon the royalties payable with respect to Net Sales of such Licensed Product sold by Jazz, its Affiliates and its Sublicensees in such country shall be reduced by [***] of the royalties otherwise owed Amicus continues to Codiak pursuant be obligated to this Section 8.10. In addition, if in any country in the Territory during the Royalty Term for a Licensed Product for such country, a Biosimilar/Generic Product is sold in such country and, according make royalty payments to a reasonable information source or reasonable proxy mutually agreed by the Parties, the units sold of all Biosimilar/Generic Products, collectively, exceed [***] or more of the unit Third Party under an Existing In-License with respect to sales of such Licensed Product in such country, then thereafter, (x) Amicus shall promptly notify Shire of the royalties payable with respect to Net Sales amount of such royalty rate for sales of such Licensed Product sold by Jazz, its Affiliates and its Sublicensees the period for which it is obligated to make such payments in such country and (y) within thirty (30) days after receipt of such notice Shire shall notify Amicus of its election to (1) terminate its sublicense under such Existing In-License in which case such sublicense will terminate whereby no further royalties shall be reduced by due from Shire for sales of such Licensed Product in such country or (2) [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. -44- make royalty payments to Amicus for the amounts owed by Amicus under such Existing In-License for the period so specified in the notice provided under subsection (y) above and at the lower of the royalties otherwise owed to Codiak pursuant to this Section 8.10. The reductions provided for by this Section 8.10.2(aroyalty rate so specified in such notice and the applicable rate specified in subsection (b) shall be calculated using the methodology outlined in Exhibit D.above.

Royalty Reductions. (a) In the event that, during the Royalty Term for a Licensed Product If and a country, (i) at the time of the First Commercial Sale of such Licensed Product in such country there is no Valid Claim that is infringed by the sale of such Licensed Product in such country for so long as there is no such Valid Claim, or (ii) if any such Valid Claim did exist as of such First Commercial Sale or thereafter but such Valid Claim has expired or otherwise no longer meets a Biosimilar Product being sold by a Third Party in a Calendar Quarter in a country in the definition of Valid ClaimTerritory, then for any royalty payments made during the period when the condition set forth in (i) or (ii) exists with respect to such Licensed Product and such country, the royalties otherwise payable with respect by Takeda to Net Sales of such Licensed Product sold by Jazz, its Affiliates and its Sublicensees MTEM in such country pursuant to Section 6.4.1 shall be reduced by [***] the percent set forth below of the royalties amounts otherwise owed to Codiak pursuant to this Section 8.10. In addition, if in any country in the Territory during the Royalty Term owed: Biosimilar Products unit volume sales for a Licensed Product for such country, a Biosimilar/Generic Product is sold in such country and, according to a reasonable information source or reasonable proxy mutually agreed by the Parties, the units sold of all Biosimilar/Generic Products, collectively, exceed [***] or more of the unit sales of such each Licensed Product in such country, then thereafteras a percentage of total sales of Licensed Products, on the royalties payable with respect to Net Sales of such Licensed Product sold by Jazzone hand, its Affiliates and its Sublicensees Biosimilar Products, on the other hand, in such country shall be reduced by Reduction Rate [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] The Parties will select a mutually agreeable independent Third Party to identify and calculate the Biosimilar Products unit volume sales for each Licensed Product in a Calendar Quarter in a country in the Territory and such unit volume sales amounts shall be included in each royalty report provided for under Section 6.11. In the event that such independent Third Party is not available or otherwise able to accurately determine or calculate the Biosimilar Product unit volume sales, Takeda shall calculate the Biosimilar Product unit volume sales based on available data in good faith. In the event MTEM disputes in good xxxxx Xxxxxx’x calculation of any Biosimilar Product unit volume sales for a Licensed Product in a country in the royalties otherwise owed Territory, MTEM may by written notice to Codiak Takeda require, at MTEM’s cost, that such dispute be resolved in accordance with Section 12.3 by and submitted to a panel of experts; provided, that Takeda shall have the right to recover royalty reductions pursuant to this Section 8.106.4.2(a) if it prevails after resolution of any such dispute, by offsetting the excess payments with Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. The reductions provided for future royalty payments owed to MTEM or obtaining a refund from MTEM, as elected by this Section 8.10.2(a) shall be calculated using the methodology outlined in Exhibit D.Takeda.